Close Menu

NEW YORK – Precision medicine company IDEAYA Biosciences said on Wednesday that it is collaborating with Pfizer in an upcoming clinical trial evaluating IDE196 in combination with MEK inhibitor binimetinib (Pfizer, Array Biopharma's Mektovi) for patients with GNAQ or GNA11 hotspot-mutated solid tumors such as uveal melanoma and colorectal cancer. The companies expect the trial to start in mid-2020.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.